GSEP
SRPT icon

Golden State Equity Partners’s Sarepta Therapeutics SRPT Stock Holding History

Golden State Equity Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25
Closed -$544 – 1574
2026
Q1 		$544 Buy
+25
New +$484 ﹤0.01% 1874

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Golden State Equity Partners's SRPT Position: Q2 2026 in Review

Golden State Equity Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 25 shares — an estimated $544 sold.

Golden State Equity Partners first reported a position in SRPT in Q1 2026 and held it in 1 quarter. The position peaked at $544 in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Golden State Equity Partners reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 25 Sarepta Therapeutics shares in Q2 2026, an estimated $544.
  • Golden State Equity Partners first reported a position in Sarepta Therapeutics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Sarepta Therapeutics position peaked at $544 in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.